• Revumenib 110mg

Revumenib 110mg

SKU:52254

Revumenib is used for adults and children aged 1 year and older with acute leukaemia that has a KMT2A translocation and has come back or not responded to treatment.

It is also used for adults and children aged 1 year and older with relapsed or refractory acute myeloid leukaemia that has an NPM1 mutation and no satisfactory alternative treatment options.

Usual dose range: for people weighing 40kg or more, 160mg to 270mg twice daily depending on interacting medicines; smaller patients receive body-size-based twice-daily doses.


Indications vary by country and change over time; this website contains information for general patient information and should be checked against local prescribing information before clinical use.

Verification Approach: Each indication and usual dose-range sentence was drafted from at least two recognised medicines information sources, usually FDA/DailyMed or an FDA label plus EMA/eMC, MedlinePlus, Mayo Clinic, Cancer Research UK, NCI/ Cancer.gov, or another reputable medicines-information source. Doses are general adult/patient-information ranges and must not be used to prescribe or change treatment.


  • FDA/DailyMed prescribing information and FDA Oncology/Hematology approval notifications.
  • EMA and UK eMC Summary of Product
    Characteristics and patient leaflets where available.
  • NCI Cancer Drug Information/Cancer.gov and Cancer Research UK medicine information where available.
  • MedlinePlus, NHS/NICE, and other national medicines information for non-oncology or immune/respiratory medicines.
  • Peer-reviewed FDA approval summaries or manufacturer regulatory notices for very new, withdrawn, or region-specific
    indications.